FDA General Wellness Guidance 2026: What Wearable and Digital Health Companies Can and Can’t Do Now

---

If you’re building a wearable, wellness app, smart ring, recovery tracker, or connected health platform, FDA just updated the playbook — and the changes matter. On January 6, 2026, FDA issued a revised final guidance replacing its 2019 General Wellness policy. The update doesn’t rewrite the rules, but it meaningfully clarifies what companies using non-invasive sensing technology can do, what the blood pressure enforcement landscape looks like after the July 2025 WHOOP Warning Letter, and where the guardrails are.

This post breaks it down in plain terms and tells you what to watch out for.

---

Five Things to Know Right Now

Before the full analysis, here are the five most practical takeaways:

1. The basic framework hasn’t changed. FDA continues to say it won’t actively examine low-risk general wellness products for medical device compliance — including registration and listing, premarket clearance, labeling requirements, quality systems, and adverse event reporting. If your product fits the policy, you get meaningful regulatory breathing room.

2. Non-invasive sensors now have clearer guidance. The 2026 update explicitly addresses smartwatches, wearables, and apps that estimate physiologic parameters like blood pressure, heart rate variability, or oxygen saturation using optical or other non-invasive sensing. Some of these products can qualify as general wellness products — but not automatically, and not just because you add a disclaimer.

3. Blood pressure is still dangerous territory. FDA’s July 2025 Warning Letter to WHOOP and a subsequent FDA Safety Communication make clear that blood pressure features tied to clinical positioning remain under active scrutiny. The 2026 guidance creates more room than 2019, but it is not a green light for blood pressure claims.

4. Intended use controls everything. FDA looks at your entire product ecosystem — website copy, app notifications, onboarding screens, investor decks, social media, and how users actually engage with the data — not just your formal label. A disclaimer buried in terms of service will not fix a product that functions like a clinical monitoring tool.

5. Validation is now a real expectation. FDA expects physiologic outputs to be validated before they reach users, even for wellness products. You need a substantiation file. You just can’t market that validation as “medical grade” or “clinical accuracy.”

---

What Is the General Wellness Policy — and Why Does It Matter?

Under the Federal Food, Drug, and Cosmetic Act (FDCA), products that fit the definition of a “medical device” are subject to extensive regulatory requirements: registration, 510(k) clearance or premarket approval, quality system compliance, labeling rules, and post-market surveillance. For an early-stage company or a startup launching a wellness product, those requirements can be prohibitive.

The General Wellness guidance is FDA’s statement that it does not intend to examine whether certain low-risk products are medical devices or enforce medical device requirements against them. Specifically, FDA references 21 C.F.R. Part 807 (registration and 510(k) premarket notification), 21 C.F.R. Part 801 (device labeling), 21 C.F.R. § 809.10 (labeling for in vitro diagnostic products, applicable where the product also qualifies as an IVD), 21 C.F.R. Part 820 (the Quality Management System Regulation, now operative following the February 2, 2026 compliance date), and 21 C.F.R. Part 803 (Medical Device Reporting).

The policy does not eliminate FDA’s authority. It reflects FDA’s enforcement priorities and its recognition that low-risk wellness products serve legitimate purposes and don’t warrant the same oversight as clinical diagnostic tools. It can be pulled back — and FDA’s enforcement activity in 2025 shows it will be, when companies push too far.

The non-device software exclusion in FDCA § 520(o) — a provision created by the 21st Century Cures Act — codified related protections for certain software functions, including general wellness software. The General Wellness guidance complements and overlaps with that statutory framework.

---

The Two-Part Test: Both Requirements Must Be Met

For a product to qualify for the general wellness policy, it must satisfy two conditions.

First, it must be intended only for general wellness use. General wellness intended use falls into one of two buckets: (1) maintaining or encouraging a general state of health or a healthy activity — weight management, physical fitness, relaxation, stress management, mental acuity, sleep management, and similar purposes — or (2) relating a healthy lifestyle choice to reducing the risk or impact of a chronic disease or condition, but only where that relationship is well established and broadly accepted.

Second, it must present a low risk to the safety of users and other persons. A product is not low risk if it uses invasive technology, is implanted, or uses technologies that pose safety concerns without specific regulatory controls (lasers, certain radiation-emitting devices).

Both conditions must be present. A product that is low risk but positioned for disease treatment or management doesn’t qualify. A product that promotes general wellness but uses invasive or inherently risky technology doesn’t qualify either.

---

What Changed: FDA Now Addresses Non-Invasive Sensing Directly

The most important update in the 2026 guidance is practical clarity for products that use non-invasive sensing — the technology powering most modern wearables and connected health devices.

The 2019 guidance gave little direction on this. The 2026 guidance explicitly acknowledges that a product using optical sensing or similar non-invasive technology may estimate or output physiologic parameters — including values like blood pressure trends, oxygen saturation, heart rate variability, and related metrics — and may still qualify as a general wellness product, provided it is intended solely for wellness use and remains low risk.

For companies in this space, this is meaningful. It means FDA is not saying “any product that outputs a physiologic value is automatically a medical device.” It is saying the analysis depends on how the product is designed, what it claims, what it shows the user, and what the user is expected to do with the information.

FDA confirmed at its February 2026 public town hall on the guidance that the core policy framework remains the same, but that the addition of non-invasive sensing guidance reflects the evolution of the wellness technology market.

This is an opening, but it comes with guardrails — and FDA has demonstrated it will use enforcement action when companies misread how wide the opening is.

---

The Blood Pressure Issue: Course Correction, Not Clearance

In July 2025, FDA issued a Warning Letter to WHOOP, Inc. regarding its Blood Pressure Insights feature. FDA’s position was direct: the feature was a device because it was intended to measure or estimate blood pressure, blood pressure measurement is inherently associated with hypertension and hypotension (conditions FDA regulates), and that association cannot be undone by adding disclaimers. FDA cited the existing blood pressure device classification at 21 C.F.R. § 870.1130 and concluded the product required marketing authorization that WHOOP had not obtained.

FDA followed that action with a Safety Communication warning consumers not to rely on unauthorized blood pressure features in wearable devices, including smartwatches and smart rings, for clinical decisions.

The 2026 guidance does not reverse those positions. What it does is refine the analytical framework. FDA appears willing to recognize that a non-invasive wearable may output blood pressure-related values — as trends, ranges, baselines, or wellness context — if the product avoids clinical positioning, diagnostic thresholds, disease management framing, and substitution claims.

Read carefully: that is not “blood pressure is now wellness-friendly.” It is “blood pressure-adjacent outputs may be possible in a wellness product if the intended use, interface, claims, validation, and risk profile are all carefully controlled.” The distinction matters, and companies that miss it will get Warning Letters.

---

What Pushes a Wellness Product Back Into Device Territory

FDA’s guidance identifies specific features that remove a product from the general wellness policy. A product is not a general wellness product if it is intended to measure, estimate, or report physiologic values for medical or clinical purposes — screening, diagnosis, treatment monitoring, alerting, or management of a disease or condition.

Red flags in labeling, advertising, interface design, or functionality include:

• References to specific diseases, clinical conditions, or diagnostic thresholds
• Alerts or push notifications that recommend specific clinical action
• Treatment guidance or medication-related instructions
• Claims of clinical equivalence or “medical grade” accuracy, or statements implying the product substitutes for an FDA-authorized device
• Intended-use language targeting diagnosis, screening, monitoring, or disease management

This means you cannot disclaim your way to compliance. FDA will look at the whole product experience — website copy, onboarding screens, dashboards, push notifications, app-store descriptions, investor presentations, user instructions, customer support scripts, and social media. If the practical effect is that users are prompted to act as if they’re using a clinical tool, FDA will treat it as one.

One practical illustration from FDA’s town hall guidance: a product may tell a user, “Your resting heart rate was high over the past few days — you should check with your doctor if this is unexpected.” What it should not do is use red/yellow/green clinical-style color coding, name a specific condition, attach a diagnostic threshold, or frame the notification as something requiring urgent medical intervention.

---

Validation: You Need It — But Be Careful How You Talk About It

The 2026 guidance introduces a validation expectation that wasn’t explicitly framed this way in prior versions. FDA states that products using non-invasive sensing should not include physiologic values that mimic clinically-used values unless those values are validated — through manufacturer testing or peer-reviewed literature.

At the February 2026 town hall, FDA added practical detail: validation may be supported through manufacturer testing alone, through publication in a peer-reviewed journal, or both. FDA encouraged public disclosure of validation results and stated that if validation data is not public, FDA may request a summary.

This creates a strategic tension. You need enough validation to substantiate your wellness outputs responsibly. You cannot market that validation as proof of clinical-grade accuracy or equivalence to an FDA-cleared device — because that language would itself push the product toward device territory.

The compliance strategy here is to distinguish clearly between three things: internal substantiation (what you’ve tested and documented), appropriate technical disclosure (what you say in clinical or peer-reviewed contexts), and external marketing claims (what you show users and the public). Keep those lanes separate.

---

Invasive Technologies Are Still Outside the Policy — Full Stop

The 2026 guidance makes clear that the low-risk requirement excludes products that penetrate or pierce the skin, are implanted, or use technologies that FDA believes require specific regulatory controls to manage safety.

FDA uses a compelling example: a wearable product that estimates blood glucose for nutritional purposes using a minimally invasive microneedle. The product is contraindicated for diabetics and pre-diabetics, and it is positioned as a nutritional insight tool, not a diagnostic device. Despite that wellness positioning, FDA concludes it falls outside the general wellness policy because the microneedle penetrates the stratum corneum — making it not low risk in FDA’s assessment.

This is important for any company working on glucose monitoring, lactate tracking, hydration analysis, hormone sensing, or metabolic biomarkers using any technology that breaks the skin barrier. A wellness claim does not rescue a product if the underlying technology introduces risks FDA considers to require regulatory oversight.

---

What Should Your Company Do Now?

If you are launching, revising, or assessing a wellness product in the wearable or digital health space, these are the steps that matter:

Conduct a full intended-use review. This should cover every touchpoint where users or the public encounter claims about your product: the name, the website, the app-store listing, the onboarding flow, the device interface, dashboards, push notifications, disclaimers, instructions for use, influencer and partnership materials, and customer support scripts. FDA’s intended-use analysis at 21 C.F.R. § 801.4 reaches all of these.

Separate wellness insights from clinical interpretation. A product may help a user understand trends in sleep, recovery, activity, or stress. Unless it has appropriate FDA marketing authorization, it should not diagnose a condition, screen for disease, monitor a disease state, recommend treatment, or imply that it substitutes for an FDA-cleared or approved product.

Be careful with colors, thresholds, and alerts. Red/yellow/green zones, disease-linked numerical cutoffs, urgent push notifications, and repeated abnormality alerts can make a wellness feature function as clinical monitoring in FDA’s eyes, regardless of how it’s labeled.

Build and maintain a validation file before marketing. Even for a wellness product, document the testing and evidence that supports your physiologic outputs and algorithm performance. Maintain that file separately from your marketing claims.

Consider a Pre-Submission to FDA if you have questions. A Pre-Submission — commonly called a Pre-Sub or Q-Sub — is a formal meeting request to FDA that allows you to get the agency’s views on a regulatory question before you finalize your product design or launch. FDA confirmed at the February 2026 town hall that companies with questions about the updated guidance should consider submitting a Pre-Submission to the relevant review division, coordinated through FDA’s Digital Health Center of Excellence. [If you want help evaluating whether a Pre-Sub makes sense for your product, contact us.]

---

The Bottom Line

The 2026 General Wellness guidance is an opening with guardrails, not a blanket clearance. It may allow more wearable and digital health companies to operate outside active medical device regulation — particularly where products use non-invasive sensing to support fitness, recovery, sleep, stress, nutrition, or performance insights.

But it does not eliminate FDA risk. In some respects, it raises the bar. FDA is now looking at whether a product mentions a disease name, how physiologic outputs are displayed, whether values resemble clinical measures, how users are prompted to act on the data, whether validation exists, and whether marketing implies medical use. The WHOOP Warning Letter is a clear signal that FDA will enforce when companies overreach.

The question is no longer simply whether you can call your product “wellness.” The better question is whether you can demonstrate — across the entire product lifecycle — that it is intended solely for general wellness use, remains low risk, and does not function as an unauthorized medical device.

That is where careful regulatory strategy makes the difference between a compliant launch and an expensive enforcement problem.

If you’re not sure where your product stands, we can help. Our regulatory attorneys work with wellness, wearable, and digital health companies at every stage — from pre-launch classification reviews to responding to FDA enforcement. Schedule a consultation today. You can also learn more about our medical device regulatory services.

---

Frequently Asked Questions

Does my wellness app need FDA clearance? Not necessarily. Under FDA’s General Wellness policy, software apps intended solely for general wellness purposes — like fitness tracking, stress management, or sleep monitoring — and that present a low risk to users may not require FDA clearance. The key factors are intended use and risk level. If your app makes claims that relate to diagnosing, treating, or managing a disease or medical condition, it will likely need marketing authorization.

What is the FDA general wellness policy? The General Wellness policy is FDA’s formal statement that it does not intend to examine whether low-risk general wellness products qualify as medical devices or enforce standard medical device requirements against them. It covers products intended only for general wellness use that present a low risk. The policy does not override FDA’s authority — it reflects enforcement priorities. FDA can and does take action when companies use the policy as cover for products that function as clinical tools.

Does the 2026 guidance apply to smartwatches and wearables? Yes. The 2026 update specifically addresses non-invasive sensing technologies of the kind used in smartwatches, smart rings, and connected wearables. FDA clarified that products using optical or other non-invasive sensing to estimate physiologic parameters may qualify as general wellness products — but only if the product is intended solely for wellness use, remains low risk, avoids clinical positioning, and does not include output values that mimic clinical measures unless those values are validated.

Can a blood pressure wearable qualify as a general wellness product? It depends on how the product is designed, what it claims, and how it is marketed. After the July 2025 WHOOP Warning Letter, FDA made clear that blood pressure features tied to clinical claims, disease monitoring, or diagnostic positioning require marketing authorization. The 2026 guidance creates analytical room for blood pressure-related wellness outputs (trends, baselines, wellness contextualization) that avoid clinical framing — but this is a high-risk area requiring careful regulatory strategy, not a self-service checkbox.

What is a Q-Submission and should I file one? A Q-Submission (also called a Pre-Submission or Pre-Sub) is a formal request to FDA for a meeting or written feedback on regulatory questions about your product before you submit a full application or finalize your product design. It is free and non-binding — FDA gives its views, but you are not required to follow them. FDA specifically recommended Q-Submissions for companies with questions about how the 2026 General Wellness guidance applies to their product. If you are uncertain whether your product qualifies as a general wellness product, a Pre-Sub can provide meaningful regulatory certainty before you launch. Contact us to discuss whether a Pre-Sub makes sense for your situation.

What is FDCA § 520(o) and how does it relate to the general wellness guidance? FDCA § 520(o) — added by the 21st Century Cures Act — codifies statutory exclusions from the medical device definition for certain software functions, including general wellness software. The General Wellness guidance and § 520(o) overlap and complement each other: the guidance reflects FDA’s enforcement policy, while § 520(o) provides a statutory basis for some of the same exclusions. For software-based wellness products, both frameworks are relevant to the regulatory analysis.

---

This post is intended for general informational purposes and does not constitute legal advice. FDA regulatory classification is fact-specific and depends on the details of your product, intended use, and marketing. Contact an FDA regulatory attorney for advice specific to your situation.